Related Experiment Video
Updated: May 12, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Product-dependent anti-factor VIII antibodies.
S Butenas1, J Krudysz-Amblo, G E Rivard
1Department of Biochemistry, College of Medicine, University of Vermont, Burlington, VT 05446, USA.
Summary
Patients with haemophilia A (HA) develop anti-factor VIII (FVIII) antibodies, with antibody development often linked to the specific FVIII product used. This study found antibody recognition varied significantly between different recombinant FVIII (rFVIII) products.
Area of Science:
- Immunology
- Hematology
- Biochemistry
Background:
- Development of neutralizing antibodies against factor VIII (FVIII) is a significant complication in haemophilia A (HA) patients receiving replacement therapy.
- The influence of specific recombinant FVIII (rFVIII) products on antibody development is not fully understood.
Purpose of the Study:
- To investigate the presence and quantity of anti-FVIII antibodies in HA subjects' plasma.
- To evaluate antibody recognition towards three distinct commercial rFVIII products.
- To explore the correlation between antibody levels and inhibitory titres.
Main Methods:
- Plasma samples from 34 HA subjects were analyzed.
- Anti-FVIII antibodies were quantified using a Multiplex Fluorescence Immunoassay.
- Inhibitory antibody titres were measured in BU (Bethesda Units).
Main Results:
- All analyzed plasmas contained anti-FVIII antibodies, with concentrations ranging from 50 nm to 570 μm.
- Eleven of 20 subjects treated with a specific rFVIII product had inhibitory antibodies (0.8-3584 BU).
- Significant differences in antibody binding were observed across the three rFVIII products, with higher titres against the product used for treatment.
Conclusions:
- Anti-FVIII antibody development appears to be influenced by the specific rFVIII product administered.
- A substantial portion of anti-FVIII antibodies may target the B domain of FVIII.
- Further research is needed to elucidate product-specific immunogenicity in HA patients.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:10Blood Typing
Understanding an individual's blood group is a critical component of transfusion medicine. It ensures compatibility in blood transfusions, organ transplants, and even during pregnancy. Determining these blood groups involves the ABO and Rh blood typing systems, utilizing specific antigens and corresponding anti-sera to identify an individual's blood type.
Antigens are protein molecules that reside on the surface of red blood cells (RBCs). The ABO and Rh blood typing systems target antigens A,...
Antigens are protein molecules that reside on the surface of red blood cells (RBCs). The ABO and Rh blood typing systems target antigens A,...
01:26Antibody Actions
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...